Indian Tobacco Company Reports Strong Q2 2022 Performance

Aug.07.2022
Indian Tobacco Company Reports Strong Q2 2022 Performance
Indian Tobacco Company (ITC) reported strong Q2 performance with revenue and earnings growing 29% and 30.1% respectively.

According to a report from ITC (formerly known as the Indian Tobacco Company Limited, now the Indian Tobacco Company), their cigarette business achieved strong performance in the second quarter of 2022, with segment revenue and segment performance increasing by 29% and 30.1%, respectively, compared to the same period in the previous year.


Photo courtesy of Wirestock.


The Indian Tobacco Company released a statement declaring their commitment to combatting illegal trade. They plan to strengthen their market position through innovation, market segmentation, premiumization, improving product availability, and strict enforcement.


The Indian Tobacco Company has expressed encouragement towards the stable tobacco tax environment and enforcement actions taken by Indian authorities to eliminate illegal trade.


The Indian Tobacco Company stated in a press release that "as demonstrated in the past, stable cigarette taxes, supported by deterrent law enforcement actions, enable the legal cigarette industry to recover trade volumes from illegal trade, generating domestic demand for Indian tobacco, while also alleviating fiscal revenue losses.


The Indian Tobacco Company has stated that it continues to work with government agencies to develop a fair, non-discriminatory, practical, and evidence-based regulatory and taxation policy framework that balances economic benefits and tobacco control objectives. This takes into account India's unique patterns of tobacco consumption, with only a small portion of combustible tobacco production being used to manufacture cigarettes in Indian factories.


Statement:


This article is compiled from third-party information and is intended only for communication and learning within the industry.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truth or accuracy of the content. The translation of this article is only for industry communication and research purposes.


Due to limited translation abilities, the translated article may not fully reflect the original text. Please refer to the original version for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of compiled information belongs to the original media outlet and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
RELX has recently launched its disposable e-cigarette, the RELX DIVA, on online channels in South Korea, offering two nicotine strengths of 0.98% and 1.98%. Publicly available information shows the device features a 20 mL e-liquid capacity and is rated for around 30,000 puffs, alongside a 750 mAh rechargeable battery and two power modes—BOOST and ECO—at approximately 16W and 13W, respectively.
Feb.05 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Scientific talk in Bursa Nilüfer spotlights cigarette and e-cigarette addiction and youth risks
Nilüfer Municipality in Bursa held a scientific talk titled “Does Addiction Change Form? Cigarettes, E-Cigarettes and Lung Health” as part of February 9 Quit Smoking Day, aiming to raise awareness of the social impact of tobacco addiction. Experts discussed cigarette and e-cigarette addiction, risks for young people, harms of secondhand smoke for children, and health outcomes linked to tobacco use.
Feb.10 by 2FIRSTS.ai
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida AG announces largest illegal vape seizure in state history, 2,183 contraband devices seized
Florida’s attorney general announced a record-breaking statewide enforcement push against illegal vaping products, with four joint operations seizing 2,183 contraband vapes and additional nitrous oxide-related items. Regulators also reported removing thousands of noncompliant products from store shelves, while investigations remain ongoing.
Feb.09 by 2FIRSTS.ai
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA schedules online roundtable to gather small manufacturers’ input on ENDS PMTA requirements
FDA announced it will convene a Feb. 10, 2026 roundtable with small tobacco product manufacturers to gather feedback on PMTA submissions for ENDS products. The discussion will be viewable online, and a public docket is open for comments through March 12, 2026.
Feb.10 by 2FIRSTS.ai